← SynDRA
DABRAFENIB
SynDRA canonical compound SYN0029186 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | BRAF |
|---|
| Mechanism of action | RAF inhibitor |
|---|
| Indication | melanoma |
|---|
| Disease area | oncology |
|---|
All known targets
- BRAF
- LIMK1
- RAF1
- PRKD2
- LIMK2
- LYN
- MAP2K5
- MAP3K11
- MAP3K20
- MELK
- MET
- NEK1
Mechanisms of action (all sources)
- RAF inhibitor
- BRAF INHIBITOR
- Serine/threonine-protein kinase B-raf inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SYK
- AAK1
- PFKP
- NTRK1
- NUAK2
- OLA1
- OPA1
- PAICS
- PAK2
- PAK4
- PAK6
- PASK
- PCYT1A
- PDGFRB
- PDXK
- PEBP1
- PGRMC1
- NLK
- PHKG2
- PIM1
- PIM2
- PIP4K2A
- PIP4K2C
- PIR
- PKMYT1
- PKN1
- PKN2
- PKN3
- PLK1
- PRKAA1
- PRKACA
- PRKACB
- NQO2
- NEK7
- PRKAG1
- NEK6
- MAPK15
- MAPK3
- MAPK7
- MAPK8
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- CP3A7
- GPX4
- IFNG
- KSYK
- NSD2
- NTM1A
- NTMT1
- TP53
Drug classes
- Protein Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Kinase Inhibitor
- Cytochrome P450 3A4 Inducers
- Cytochrome P450 2C9 Inducers
- Cytochrome P450 2C19 Inducers
- Cytochrome P450 2C8 Inducers
- Cytochrome P450 2B6 Inducers
- Organic Anion Transporting Polypeptide 1B1 Inhibitors
- Organic Anion Transporting Polypeptide 1B3 Inhibitors
- Organic Anion Transporter 1 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- TAFINLAR
- Tafinlar
- GSK2118436B
- dabrafenib mesylate
- tafinlar
- GSK2118436
- dabrafenib mesilate
- Gsk2118436
- GSK-2118436
- GSK-2118436A
- GSK2118436A
- Dabrafenib (GSK2118436)
- UNII-QGP4HA4G1B
- GSK 2118436
- QGP4HA4G1B
- CHEBI:75045
- Dabrafenib [USAN:INN]
- GSK 2118436A
- 1195765-45-7 (free base)
- Dabrafenib (USAN)
- DABRAFENIB [USAN]
- Dabrafenib (Free Base)
- P06
- DABRAFENIB [MI]
- DABRAFENIB [INN]
- DABRAFENIB [VANDF]
- DABRAFENIB [WHO-DD]
- MLS006011052
- SCHEMBL806377
- GTPL6494
- CHEMBL2028663
- DABRAFENIB, KB-57246
- DTXSID20152499
- HMS3656D12
- HMS3672G05
- AMY10291
- BCP09341
- EX-A1320
Reported adverse events
- Abdominal pain
- Alopecia
- Anxiety
- Arthralgia
- Atrioventricular block
- Atrioventricular block complete
- Back pain
- Cardiomyopathy
- Chills
- Colitis
- Constipation
- Cough
Look up DABRAFENIB in the interactive SynDRA portal →